HomeContact Details:
David Bishop-Bailey graduated with a B.Sc. in Pharmacology in 1994 from the Kings College London. He then undertook a Ph.D. at the National Heart and Lung Institute, Imperial College with Prof. Jane Mitchell and Prof. Tim Williams leading to award of doctoral thesis on the role and regulation of cyclo-oxygenase and nitric oxide synthase enzymes in blood vessels in 1998. From 1997-1999 Dr Bishop-Bailey undertook a period of post-doctoral research at the University of Connecticut Health Center with Prof. Timothy Hla. In 1999, Dr Bishop-Bailey was awarded a British Heart Foundation Intermediate Fellowship, returning to the UK to the William Harvey Research Institute, working with Prof Tim Warner in the Cardiac, Vascular & Inflammation Research Centre. Since 1999, Dr Bishop-Bailey has obtained a British Heart Foundation Basic Science Lectureship (2002), and was promoted to Senior Lecturer (2004). Dr Bishop-Bailey is a member of British Pharmacological Society, the American Heart Association, the British Society for Cardiovascular Research, the European Vascular Biology Organisation and the Society for Leukocyte Biology. Additional profession roles include being a member of Medical Research Council College of Experts serving on the Physiological Systems and Clinical Sciences Board Special Review Panel, and serving on the editorial boards for the Journal of Pharmacological and Toxicological Methods, Prostaglandins and Other Lipid Mediators, and being an Advisory Board member for PPAR Research. Dr Bishop-Bailey currently lectures on cardiovascular and inflammatory disorders, non-steroidal anti-inflammatory drugs, nuclear receptors and the health benefits of exercise.
.
Current research interests
Dr Bishop Bailey has a broad interest in vascular biology, eicosanoid signaling, and in the regulation and function of nuclear receptors. His current research is focused in the following areas:
-
The role and regulation of peroxisome-proliferator activated receptor (PPAR) in vascular and inflammatory cells and identifying novel endogenous ligands.
-
The role and regulation of the bile acid / farnesoid X receptor (FXR). Dr Bishop-Bailey recently identified FXR in the vasculature, and in a number of cancers. Currently there are projects looking at the functions of FXR in vascular cells and in breast cancer.
-
The platelet as a novel target for nuclear receptors. We recently found platelets contain a variety of nuclear receptors including PPARs, FXR, and retinoid X receptors (RXR)s. We are investigating the platelet as a novel nuclear receptor target working via ‘non-genomic’ signalling pathways.
- Identifying the roles of epoxygenases and epoxygenases products in vascular and inflammatory cells.
- Identifying novel vascular, inflammatory and metabolic nuclear receptors and their ligands.
Dr Bishop-Bailey is particularly looking for PhD students, clinicians and researchers interested in the further development of these particular areas.
Key publications
-
Wray JA, Zeldin DC, Sugden MC, Holness MJ, Greenwood GK, Samsuddin S, Degraff LM, Bradbury JA, Warner TD, Bishop-Bailey D. (2009). The epoxygenases CYP2J2 activates PPARalpha in vitro and in vivo. PloS One. 4(10): e7421. doi:10.1371/journal.pone.0007421.
- Bishop-Bailey D. (2009). The platelet as model system for the nongenomic actions of nuclear receptors. Steroids. In press
- Bishop-Bailey D, Bystrom J. (2009). Emerging roles of peroxisome proliferator-activated receptor-beta/delta in inflammation. Pharmacol Ther. 124, 141-150.
- Piqueras L, Sanz MJ, Perretti M, Morcillo E, Norling L, Mitchell JA, Li Y, Bishop-Bailey D. (2009). Activation of PPARbeta/delta inhibits leukocyte recruitment, cell adhesion molecule expression, and chemokine release. J Leukoc Biol. 86, 115-122.
- Bishop-Bailey D. (2008) Peroxisome proliferator-activated receptor beta/delta goes vascular. Circ Res. 102, 146-147.
- Moraes LA, Swales KE, Wray JA, Damazo A, Gibbins JM, Warner TD, Bishop-Bailey D. (2007) Nongenomic signaling of the retinoid X receptor through binding and inhibiting Gq in human platelets. Blood. 109, 3741-3744.
- Piqueras L, Reynolds A, Holdivala-Dilke K, Aranatazu A, Redondo JM, Hatae T, Warner TD, Bishop-Bailey D. (2007). PPARbeta/delta ligands induce endothelial cell proliferation and angiogenesis. Arterioscler. Thromb. Vasc. Biol. 27, 63-69.
- Swales, K.E., Korbonits, M., Walsh, D.T., Carpenter, R., Warner, T.D. and Bishop-Bailey, D. (2005). The Farnesoid X Receptor is expressed in breast cancer and regulates apoptosis and aromatase expression. Cancer Res. 66, 10120-10126.
Search for more publications by David Bishop-Bailey
